Table 3

Outcome measures addressed in non-randomised clinical trials assessing continuous and intermittent administration of antistaphylococcal antibiotic treatment

Study	PFT	Chest radiography score	Clearance of S aureus from sputum	Cough frequency	Respiratory exacerbations	Antibiotic courses	Weight	Height	Clinical score	Side effects^3-151	Bacterial resistance
Continuous administration
Loening-Bauke^3-150	+	0	+	0	+	+	+	0	+	–	0
Kerrebijn	0	×	0	×	+	0	×	×	0	0	0
Wright	0	0	+	+	0	0	+	0	0	–	–
Ballestero	0	0	0	0	0	0	0	0	0	0	–

Intermittent administration
Brown	0	0	+	0	0	0	0	0	0	0	0
Shapera	0	0	+	0	0	0	0	0	0	–	0
Szaff & Hoiby	0	0	+	0	0	×	0	0	0	–	+
Jensen	0	0	0	0	0	+	0	0	0	0	+
Feigelson	0	0	+	0	0	0	0	0	0	–	+

Continuous antistaphylococcal treatment helps the clearance ofS aureus from the sputum but could lead to increased bacterial resistance while intermittent antistaphylococcal treatment helps the clearance of S aureusfrom the sputum and may reduce the risk of increasing bacterial resistance. PFT = pulmonary function tests; + = positive outcome; × = difference not observed; — = negative outcome; 0 = outcome not addressed. “Side effects” refers to direct drug related side effects, while reports of increased bacterial resistance as a side effect is recorded in the following column.
↵3-150 The study by Loening-Bauke is a randomised clinical trial in which the patients acted as their own controls.
↵3-151 Loening-Bauke observed superficial candidiasis and altered liver function tests (LFTs), Wright observed possible early acquisition ofPseudomonas aeruginosa or conversion to mucoid strains with antistaphylococcal treatment, minor gastrointestinal side effects, rash and altered LFTs, Shapera observed pain or burning at injection site, rash and minor gastrointestinal side effects, Szaff and Hoiby observed penicillin allergy and minor gastrointestinal side effects, and Feigelson observed minor gastrointestinal side effects only.